First human test for new kidney disease drug begins

NCT ID NCT07054684

Recruiting now Disease control Sponsor: Biohaven Therapeutics Ltd. Source: ClinicalTrials.gov ↗

Summary

This is an early-stage study to check if a new drug called BHV-1400 is safe for people with IgA nephropathy, a disease that damages the kidneys. The study will enroll 20 adults who have had the disease confirmed by a kidney biopsy. Researchers will closely monitor participants for any side effects or changes in lab tests to see if the drug is well-tolerated.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site-001
RECRUITING

Farmington, Connecticut, 06030, United States
Site-002
RECRUITING

Dakota Dunes, South Dakota, 57049, United States
Site-003
RECRUITING

Miami Lakes, Florida, 33016, United States
Site-004
RECRUITING

Houston, Texas, 77099, United States
Site-005
RECRUITING

Pembroke Pines, Florida, 33029, United States
Site-006
RECRUITING

Chesterfield, Missouri, 63017, United States
Site-007
RECRUITING

Leicester, LE5 4PW, United Kingdom
Site-008
RECRUITING

Lawrenceville, Georgia, 30046, United States
Site-009
RECRUITING

Hinsdale, Illinois, 60521, United States
Site-011
RECRUITING

Miami Lakes, Florida, 33172, United States
Site-012
RECRUITING

Indianapolis, Indiana, 46268, United States
Site-013
RECRUITING

Orlando, Florida, 32806, United States

Conditions

Explore the condition pages connected to this study.

IGA NEPHROPATHY